This is outstanding. It does shed some light to questions we have been asking and the answers are written there for all to see, especially the Stathmin 2 protein levels.
1. "Nuz 001 can simultaneously target TDP-43 pathology (significantly decrease cytoplasmic TDP-43 aggregation" and increase STMN2 protein levels" as well as activating Autophagy. 2. It is potential disease modifying therapy.
i look forward to the day that Nuz not only modify's the lives of those with ALS for the better, but also the lives of the shareholders that believed, and invested into this incredible "Small Molecule".
Actually, wasn't Elanco just recently posting about focusing on investing in game changing small molecule therapy? Or something to that effect?
soon enough, I am sure the hand on the clock will point to "A matter of time" that we have all been waiting for.
cheers, D
NUZ Price at posting:
14.0¢ Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)